Euan A. Ashley
B-Receptor Signaling in Cardiomyopathy
Contact Information
Stanford University School of Medicine 300 Pasteur Drive Stanford, CA 94305Brief
We hope to determine the importance of different genes (including B receptors) in anthracycline-induced cardiomyopathy. This has important benefits to patients exposed to anthracyclines, as this could help determine whether certain individuals have increased susceptibility to cardiac injury.
Recruiting Status:
RecruitingStanford Recruiting Status:
RecruitingCondition(s):
Intervention(s):
Phase:
N/AEligibility
Ages Eligible for Study:
Any Age to 40 yearsGenders Eligible for Study:
Male and FemaleHealth of Volunteers:
People with the conditions listed in this trial can participate as controls.Key Inclusion Criteria:
1.) Past exposure to anthracycline chemotherapy for cancer
2.) Echocardiogram at least six months after exposure to anthracyclines (in patients over the age of 40, the echocardiogram must be obtained within 6-48 months of anthracycline exposure)
3.) Ability to understand and the willingness to sign a written informed consent document.
We have no age, gender, or ethnic background limitations. Due to the increased frequency of cardiovascular disease from other causes in adults over 40 years, we will limit enrollment to those patients with an echocardiogram 6 - 48 months after the completion of anthracycline exposure. Children will be included and will be eligible if they have an echocardiogram at least 6 months after completion of anthracycline treatment..
Key Exclusion Criteria:
1.) Congenital heart disease (other than patent foramen ovale)
2.) Pre-existing cardiomyopathy before anthracycline administration
3.) Patients with Down syndrome
4.) Patients receiving B-blocker therapy at the time of anthracycline exposure
5.) Pregnant patients (if their echocardiogram was obtained either during pregnancy or within three months of pregnancy)
All participants will be cancer survivors. To minimize bias from post-partum cardiomyopathy, pregnant patients will be excluded if their echocardiogram was obtained during pregnancy or within three months of pregnancy. HIV-positive persons will not be excluded from the study.
Of note, some patients receive a MUGA (multigated acquisition) study to evaluate left ventricular ejection fraction. Patients who receive only a MUGA scan will NOT be included in the study ? an echocardiogram is necessary
Additional Study Details
Official Title:
B-Receptor Signaling in CardiomyopathyAnticipated start date:
11/10/2008Lead Sponsor:
Stanford UniversityInvestigator(s):
Study Type:
ObservationalPurpose:
NOTNEEDEDDuration:
Cross-sectionalSelection:
Convenience SampleTiming:
Retrospective/ProspectiveTotal Number to be Enrolled:
300Total Number to be Enrolled at Stanford:
300More Information
Secondary ID(s):
- VAR0038
Locations & Contacts
Stanford Locations & Contacts:
Stanford University School of Medicine 300 Pasteur Drive Stanford, CA 94305Non-Stanford Locations:
The Stanford website does not have any locations outside of Stanford listed for this trial. You may want to check clinicaltrials.gov for posible additional locations.
This listing was last updated:
11/4/2009PLEASE NOTE:
Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers are provided for obtaining additional information on specific clinical research trials only. If you have specific questions which require clinical expertise, please call your primary care physician. If you do not have a primary care physician please feel free to call the SHC Physician Referral Service at (800) 756-9000 or send an email.
Help